I-mab Biopharma (Hangzhou) Co., Ltd. announced that it will receive equity funding for $19 million from returning investor I-Mab on February 7, 2024. The transaction is expected to be close by the end of March 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.81 USD | +1.12% | +2.55% | -4.74% |
18/04 | Verastem Names John Hayslip as Chief Medical Officer | MT |
15/04 | I-Mab Announces Chief Medical Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.74% | 146M | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.87% | 239B | |
+8.07% | 204B | |
-7.73% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab